For many years, Becton Dickinson (NYSE:BDX) has been summarily dismissed by a lot of portfolio managers as "too boring". Well, their loss. Although the stock of this diversified health care and biosciences company could not match the pace of health care all-star Medtronic (NYSE:MDT), it stacks up quite well against the likes of Abbott Labs (NYSE:ABT), Baxter (NYSE:BAX) and many other more "exciting" names. Proof, perhaps, that the steak is more satisfying than the sizzle.

IN PICTURES: 20 Tools For Building Up Your Portfolio

A Quiet Quarter
The first quarter of 2010 was pretty much medium, with little to get excited about in either direction. Revenue growth of about 7% was in line with expectations, while the earnings per share (ex-items) were four cents ahead of the average estimate.

Results across the company's three major business lines were mixed. Strong results in diabetes care and pharmaceutical systems helped offset weakness in medical surgical systems (largely injection, infusion and infection-prevention products) in the BD Medical segment. Diagnostics saw results in cancer and STD testing offset a decline in flu testing, while cell analysis products helped boost results in the biosciences business. (For related reading, check out A Checklist For Successful Medical Technology Investment.)

New Tech Can Maintain the Momentum
It seems practically a given that Becton Dickinson will increasingly tie the future of its growth to advanced diagnostics and bio-research products. In diagnostics, the company faces stiff competition from companies like Roche (Nasdaq:RHHBY), Qiagen (Nasdaq:QGEN) and Gen-Probe (Nasdaq:GPRO) in its STD testing franchise, and Cepheid (Nasdaq:CPHD) in hospital-acquired infections.

To compete, the company plans to roll out a new molecular diagnostics platform, the BD MAX, in 2011. This automated real-time PCR platform could go a long way in tapping the fast-growing molecular diagnostics market. Of course, Cephied and Gen-Probe have their own automated systems (with Gen-Probe's new Panther expected in the U.S. in 2011), so the battle should really get interesting at that point.

Likewise, expect the company to continue to look to innovate or acquire to build up the biosciences business. With BDX's existing strength in flow cytometry, it wouldn't be surprising to see them interested in a fast-growing company like Luminex (Nasdaq:LMNX). But even if the company foregoes acquisitions (or at least acquisitions of that size), expect management to preferentially invest in a market segment whose growth should outpace that of BDX's other markets by a reasonable margin.

A Stock That Gives You Second Chances
Becton Dickinson isn't all that expensive at today's prices. That said, this is a stock that always seems to give investors a pullback of at least 10% every year. Perhaps we already saw that move when the stock went from about $80.50 around the end of last year to below to below $75 in early February, or maybe there is a second slide to come. In either case, you don't have to rush to buy this stock. It is a fine company as is, but if you can get it for 10% less, why not wait it out?

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing

    Time to Bring Active Back into a Portfolio?

    While stocks have rallied since the economic recovery in 2009, many active portfolio managers have struggled to deliver investor returns in excess.
  2. Economics

    Investing Opportunities as Central Banks Diverge

    After the Paris attacks investors are focusing on central bank policy and its potential for divergence: tightened by the Fed while the ECB pursues easing.
  3. Stock Analysis

    The Biggest Risks of Investing in Pfizer Stock

    Learn the biggest potential risks that may affect the price of Pfizer's stock, complete with a fundamental analysis and review of other external factors.
  4. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  5. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  6. Markets

    PEG Ratio Nails Down Value Stocks

    Learn how this simple calculation can help you determine a stock's earnings potential.
  7. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  8. Investing

    What’s the Difference Between Duration & Maturity?

    We look at the meaning of two terms that often get confused, duration and maturity, to set the record straight.
  9. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  10. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  1. What does low working capital say about a company's financial prospects?

    When a company has low working capital, it can mean one of two things. In most cases, low working capital means the business ... Read Full Answer >>
  2. Do nonprofit organizations have working capital?

    Nonprofit organizations continuously face debate over how much money they bring in that is kept in reserve. These financial ... Read Full Answer >>
  3. Can a company's working capital turnover ratio be negative?

    A company's working capital turnover ratio can be negative when a company's current liabilities exceed its current assets. ... Read Full Answer >>
  4. Does working capital measure liquidity?

    Working capital is a commonly used metric, not only for a company’s liquidity but also for its operational efficiency and ... Read Full Answer >>
  5. How do I read and analyze an income statement?

    The income statement, also known as the profit and loss (P&L) statement, is the financial statement that depicts the ... Read Full Answer >>
  6. Can working capital be too high?

    A company's working capital ratio can be too high in the sense that an excessively high ratio is generally considered an ... Read Full Answer >>

You May Also Like

Trading Center